贝派度酸是一种 ATP-柠檬酸裂解酶 (ATP-citrate lyase；ACL) 抑制剂，贝派度酸激活 AMPK。
包装:  500g/袋，1kg/袋，5kg/袋
供货情况: 现货供应
API Current Development Status: A3---Process Development / Scale-Up
Reference: 
Aktin major API development processes:
A1.Feasibility / Route Development
A2.Laboratory Process Development
A3.Process Development / Scale-Up
A4.GMP Clinical Development
A5.Commercial GMP Supply

[1]. Pinkosky SL, et al. AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism. J Lipid Res. 2013 Jan;54(1):134-51.
[2]. Filippov S, et al. ETC-1002 regulates immune response, leukocyte homing, and adipose tissue inflammation via LKB1-dependent activation of macrophage AMPK. J Lipid Res. 2013 Aug;54(8):2095-108.

[3].Pinkosky SL, Newton RS, Day EA, Ford RJ, Lhotak S, Austin RC, et al. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. Nat Commun. 2016;7:13457.

[4].Ray KK, Bays HE, Catapano AL, Lalwani ND, Bloedon LT, Sterling LR, et al. Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med. 2019;380(11):1022-1032.